MuonOne
01-09-2008, 04:43 PM
Child Neurology, c. 2006, 7th edition
edited by John H. Menkes, Harvey B. Sarnat, Bernard L. Maria
abstract (from pages 187-188)
"In a few families, progressive degeneration of the anterior horn cells and pyramidal tracts appears before age 20 years. . . . transmission is either autosomal dominant or autosomal recessive. . . . Recessive forms of ALS usually have a juvenile onset . . . . The most prevalent form has been mapped to chromosome 2q33 and has been designated ALS2. . . . (is t)he most likely form to be encountered in the pediactric population (and can commence) as early as 3 years of age. . . . Treatment: No treatment is available."
so I ask, do persons with hereditary ALS try rilozule, and if so, is there recognizable benefits???
A table is included that shows fALS divided into five classes lables ALS1, ALS2, ALS3, ALS4 and ALS5.
not all are terminal.
edited by John H. Menkes, Harvey B. Sarnat, Bernard L. Maria
abstract (from pages 187-188)
"In a few families, progressive degeneration of the anterior horn cells and pyramidal tracts appears before age 20 years. . . . transmission is either autosomal dominant or autosomal recessive. . . . Recessive forms of ALS usually have a juvenile onset . . . . The most prevalent form has been mapped to chromosome 2q33 and has been designated ALS2. . . . (is t)he most likely form to be encountered in the pediactric population (and can commence) as early as 3 years of age. . . . Treatment: No treatment is available."
so I ask, do persons with hereditary ALS try rilozule, and if so, is there recognizable benefits???
A table is included that shows fALS divided into five classes lables ALS1, ALS2, ALS3, ALS4 and ALS5.
not all are terminal.